Answers are grounded in this paper and cite their sources.
Dear Editor, Calcinosis (cutis), defined as sub-epidermal deposition of calcium salts, is a currently untreatable manifestation of SSc [1], occurring in the order of 20–40% of patients [2]. The calcium containing deposits often form painful lumps, especially at pressure points, and the lumps can ulcerate through skin and become infected [3, 4]. There is very little evidence base for the different treatments that have been proposed [5]. Current treatment relies mainly on early antibiotic treatment of infection and surgical debulking [6]. Clinical trials aimed at developing effective therapies are badly needed, yet are challenging for many reasons including: the need to further elucidate pathogenesis of calcinosis in order to develop targeted therapies; the lack of validated outcome measures (although these are in development [7, 8]); and the heterogeneity of calcinotic deposits within and between patients. Against this background, more research is required. But as a first step, it is important to benchmark the clinical burden of calcinosis. This is a key issue, because those with no direct experience of calcinosis may not realize how painful and disabling calcinosis can be, and may (wrongly) feel that calcinosis is a relatively minor issue in the context of a potentially life-threatening multisystem disease. Our aim was to conduct a survey (following the principles of the Declaration of Helsinki) to gauge the thoughts and opinions of patients with calcinosis regarding the clinical burden of calcinosis, and of the treatment of their calcinosis.
No takes yet. Share an insight, caveat, or question.
Pearson et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: